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Abstract
Background: Identifying disease causing genes and understanding their molecular mechanisms
are essential to developing effective therapeutics. Thus, several computational methods have been
proposed to prioritize candidate disease genes by integrating different data types, including
sequence information, biomedical literature, and pathway information. Recently, molecular
interaction networks have been incorporated to pre d i c td i s e a s eg e n e s ,b u tm o s to ft h o s em e t h o d s
do not utilize invaluable disease-specific information available in mRNA expression profiles of
patient samples.
Results: Through the integration of protein-protein interaction networks and gene expression
profiles of acute myeloid leukemia (AML) patients, we identified subnetworks of interacting
proteins dysregulated in AML and characterized known mutation genes causally implicated to AML
embedded in the subnetworks. The analysis shows that the set of extracted subnetworks is a
reservoir rich in AML genes reflecting key leukemogenic processes such as myeloid differentiation.
Conclusion: We showed that the integrative approach both utilizing gene expression profiles and
molecular networks could identify AML causing genes most of which were not detectable with gene
expression analysis alone due to the minor changes in mRNA level.
Background
Mining disease-causing genes and elucidating their
pathogenic molecular mechanisms are of great impor-
tance for developing effective diagnostics and therapeu-
tics [1-5]. Along with many genetic and genomic studies
aimed at identification of disease genes (e.g. linkage
analysis, cytogenetic studies, microarray experiments,
proteomic studies), several computational methods have
been proposed to prioritize candidate genes based on
various information including sequence similarity,
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G i v e nas e to fg e n e sk n o w nt ob ei n v o l v e di nd i s e a s e ,
these methods typically score similarities between
candidate genes and known disease genes in terms of
various genomic features.
Recently, accumulated knowledge about molecular
interaction networks in human cells such as protein-
protein, and protein-DNA interactions has been utilized
to predict disease genes [6-8,10,12-14]. The previous
studies have incorporated topological characteristics of
known disease genes such as degrees in networks [14],
the overlap between interaction partners of candidate
genes and those of known disease genes [6], the
probability of candidate genes to participate in the
same protein complexes with known disease-causing
genes [10], or the distribution of distances from
candidate genes to known disease genes [13].
Despite their successful performance in general, for some
specific diseases of our interest, such as acute myeloid
leukemia (AML), the performance is not satisfactory
(AUC = 0.55 by Radivojac et al. [13]). We hypothesized
that integrating molecular networks with mRNA expres-
sion profiles from patients might help delineate disease-
specifically dysregulated molecular subnetworks con-
taining disease-causing mutation genes. Chuang et al.
supported this hypothesis showing the identified subnet-
works included significantly enriched known breast
cancer mutation genes [15]. Mani et al. proposed
another method predicting oncogenes in B-cell lympho-
mas integrating both molecular interactions and mRNA
expressions [16].
Here, we identified molecular subnetworks dysregulated
in AML patients which were associated with key
leukemogenic processes such as myeloid differentiation.
We also evaluated the enrichment of known AML-
causing mutation genes within the subnetworks, and
found that the subnetworks contain significant fraction
of known AML genes (mostly non-differentially
expressed) embedded among the interconnections of
differentially expressed genes. In addition, several
c h a r a c t e r i s t i c so fA M Lg e n e si nt h es u b n e t w o r k sw e r e
reported in this study, which can be utilized to build
prediction models for unknown AML genes.
Results and discussion
Identification of subnetworks perturbed in AML
The method to find subnetworks of AML is similar to that
of our previous work [15], and visualized in Figure 1. We
overlaid the gene expression values of each gene on its
corresponding protein in the protein-protein and protein-
DNA interaction network and searched for subnetworks
whose combined activities across the patients have high
perturbation scores (PS) starting from each node in a
greedy fashion. The gene expression profiles used cDNA
platforms where each expression value of gene gi in patient
pj (gij) is the mean log ratio of intensities from Cy5-labeled
mRNA of the patient and Cy3-labeled reference mRNA.
Expression values were normalized for each gene across
patients to have mean 0 and standard deviation 1 (zij). We
took absolute values of expression levels to measure
perturbation effect regardless of the direction of changes
(i.e. up or down). The perturbation score was defined as
the mean over standard deviation of an activity vector
across samples where each activity value was the averaged
expression level of genes participating in each subnetwork
Mk and is denoted as S(Mk) in Figure 1. Subnetworks with
higher mean and smaller variance of activity levels are
considered more perturbed in AML samples.
AML subnetworks associated with key leukemogenic
processes
Through the search for sutnebworks perturbed in AML
patients, we identified 269 subnetworks (p < 0.05)
comprising of 859 genes whose functions are associated
with AML development processes such as myeloid
differentiation, cell signaling of growth and survival,
cell cycle, cell and tissue remodeling. Within the
significant AML subnetworks, we found many of already
known AML-causing mutation genes. Figure 2 shows
examples of subnetworks containing known AML genes
such as JAK2, JAK3, PDGFRB, and CREBBP, and their
representative biological processes. Especially, a severe
block in myeloid differentiation is known to be the
hallmark of AML.
AML subnetworks enriched for known AML causing genes
We have evaluated the enrichment of known AML genes
in significant subnetworks in a systematic way. We
compiled 62 genes known to be causally mutated in
AML from Sanger Cancer Gene Census. 150 out of
269 subnetworks included at least one AML gene, and
49 subnetworks included two or more AML genes. As
shown in Figure 3, subnetworks were much more
significantly enriched for AML causing mutation genes
than the conventional gene-expression analysis alone
without considering molecular interactions (p value
P=7 . 1 4 e - 6v s .P=0 . 0 4 ) .
Characteristics of AML genes in the subnetworks
Table 1 lists 18 known AML genes detected in perturbed
subnetworks along with the number of subnetworks
including a designated gene and the magnitude of
differential expression in its mRNA level (DES) for
each gene. JAK3, KIT, EVI1, and CREBBP appeared in
more than 10 subnetworks while other genes were
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extremely high frequency (110) has been reported to
have great biological importance in AML pathogenesis
through gain-of-function JAK3 mutations (e.g.
JAK3A572V, JAK3V722I, JAK3P132T) activating signal
transduction [17]. Mutations in KIT having the second
highest frequency (43) were also found in more than
30% of patients with de novo AML [18]. The appearance
frequency of an AML gene in subnetworks was more
correlated with the magnitude of its DES score (correla-
tion coefficient r = 0.43) than the number of interacting
partners, the node degree (r =0 . 0 1 ) .
We examined whether AML genes captured in subnet-
works might have high degrees in the network because
that property has been used to predict unknown disease
genes in other diseases previously (Figure 4a). The figure
shows that all known AML-causing genes (AML) and
AML genes captured in subnetworks (AML_Network)
have significantly more interaction partners than all
genes in the network (P = 1.22e-6, and P = 2.34e-6,
respectively). AML genes found in subnetworks have
slightly higher degree than AML genes not captured in
subnetworks (P = 0.02). The mean and median degrees
of all genes in the network are 9 and 4, while those of
18 AML genes are 51 and 27. Though this result supports
that known AML genes have tendency of high network
degrees, low degree AML genes such as RPL22, and
TRIP11 also appeared in the subnetworks.
Finally, we investigated the differential expression of
AML genes in mRNA levels (Figure 4b). There was no
significant difference between each group of genes, and
all known AML genes and those found in subnetworks
except FLT3, and JAK3 did not show mRNA level
aberrations. This result shows that gene expression
alone does not provide enough information to predict
unknown AML-causing mutation genes. However, our
integrative approach could capture non-differentially
expressed AML genes in subnetworks if they were
Figure 1
Schematic overview of the subnetwork identification. Schematic overview of the subnetwork identification.
The mRNA expression levels of each gene were overlaid on its corresponding protein in the network and subnetworks
whose combined activities across the patients have high perturbation score were searched. An activity level (akj)f o ra
subnetwork Mk in j
th sample was defined as the mean expression levels with the square-root of the number of participating
genes in the denominator. The perturbation score S(Mk) for the subnetwork was then calculated as the mean over the
standard deviation of the activity levels across patients.
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teins yielding subnetworks with high perturbation
scores.
Conclusion
We have demonstrated that integration of condition-
independent molecular networks extracted from various
types of cells and experiments under different condi-
tions, and disease-specific mRNA expression profiles of
AML patients enables the dissection of pathogenic
modules of interacting proteins reflecting key leukemo-
genic processes. In addition, the dissected modules are
enriched for AML-causing mutation genes most of which
are not detectable with gene expression analysis alone
Figure 2
Examples of subnetworks containing known AML mutation genes. Nodes and links represent human proteins
and protein interactions, respectively. The color of each node shows the degree of mRNA level change in AML patients.
Known AML mutation genes are marked with the diamond shape.
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tion of subnetworks perturbed in AML patients can
provide novel molecular hypotheses underlying AML
etiology, and investigated characteristics of known AML
genes appearing in the subnetworks can be exploited to
predict unknown AML-causing genes.
Methods
Protein-protein interaction networks
We downloaded the PPI network from the PhenoPred
websitebyRadivojacetal.[19].Itconsistsof41456physical
interactions among 9142 proteins assembled from Human
Protein Reference Database (HPRD) [20], the Online
Predicted Human Interaction Database (OPHID) [21],
and studies by Rual et al. and Stelzl et al. [22,23].
mRNA expression profiles of AML patients
Gene expression profiles of 65 peripheral-blood sam-
ples and 54 bone marrow specimens from 116 adult
patients with AML were downloaded from Gene
Expression Omnibus (GSE425) whose expression
values are log ratios (base 2) of mean intensities of
patient samples vs. common reference mRNA [24].
Gene identifiers of three cDNA microarray platforms
(GPL317,318,319) were mapped to gene symbols using
accompanied gene annotation files from GEO yielding
6987 gene symbols with expression levels in at least one
of three platforms.
Figure 3
The enrichment of AML mutation genes in
subnetworks. 18 out of 62 AML genes (29.03%) were found
in 269 subnetworks including 859 genes, and their
enrichment was significant (p-value P = 7.14e-6) through the
hypergeometric test (the probability of 18 AML genes out of
all 62 are found in the subnetworks including total 859 genes
out of 9142 genes in the whole network). In contrast, only
two AML genes (FLT3, JAK3) (3.23%) were found among
859 top differentially expressed genes in their mRNA levels
(P = 0.04).
Table 1: AML mutation genes in subnetworks
Genes Number of Subnetworks Degree DES
+
JAK3* 110 32 2.73
KIT 43 54 1.97
EVI1 16 7 1.27
CREBBP 14 209 1.5
EP300 7 216 2.36
BCR 2 32 1.41
FLT3** 2 11 3.58
NSD1 2 6 1.14
PTPN11 1 109 1.07
JAK2 1 87 N/A
PDGFRB 1 56 0.33
NPM1 1 33 0.37
RUNX1 1 22 0.68
GATA2 1 20 1.58
PICALM 1 8 0.44
FNBP1 1 7 2.05
RPL22 1 3 1.08
TRIP11 1 2 1.29
+DES means the degree of change in its mRNA level for each gene.
Genes with the absoluteDES ranked within top 5% are marked with **,
and genes within top 10% are marked with *.
Figure 4
(a) Degrees and (b) mRNA expression changes of
AML genes. Each figure shows node degrees and
magnitudes of differential expression (DES) for AML-causing
mutation genes found in subnetworks (AML_Network), all
known AML mutation genes (AML), and all genes in the
whole network. The bottom and top of each box are first
and third quartiles, and the band near the middle of the box
is the median. Whiskers extend to at most 1.5 times the
inter-quartile range. Beyond the whiskers, all outliers are
shown in open circles. The statistical significances for
differences between two groups of genes (e.g.
AML_Network vs. All genes) measured by non-parametric
Wilcoxon rank-sum test are denoted below the labels of
gene groups.
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We compiled two sets of AML-associated genes: 14 genes
downloaded from PhenoPred web site originally col-
lected from OMIM [25], Swiss-Prot [26], and HPRD [20]
by Radivojac et al. (Disease Ontology ID: 9119) [19],
and 62 genes whose somatic and germline mutations are
causally implicated in AML patients downloaded from
Sanger Cancer Gene Census [27], and also appearing in
our PPI network.
Significance evaluation of subnetworks
To evaluate the significance of the identified subnet-
works, we performed the same search procedure over
1000 random trials in which the expression vectors of
individual genes are randomly permuted in the network.
The p value of each real subnetwork was calculated as the
fraction of random subnetworks having higher PS scores
than the designated real subnetwork among all random
subnetworks. We considered subnetworks with the
p-value P < 0.05 significant in this work.
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